Wealthfront Advisers’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $956K | Buy |
11,530
+1,479
| +15% | +$123K | ﹤0.01% | 687 |
|
|
2025
Q1 | $815K | Sell |
10,051
-1,115
| -10% | -$90.4K | ﹤0.01% | 700 |
|
|
2024
Q4 | $1.01M | Sell |
11,166
-1,924
| -15% | -$173K | ﹤0.01% | 666 |
|
|
2024
Q3 | $1.29M | Sell |
13,090
-39
| -0.3% | -$3.85K | ﹤0.01% | 600 |
|
|
2024
Q2 | $1.22M | Sell |
13,129
-491
| -4% | -$45.5K | ﹤0.01% | 589 |
|
|
2024
Q1 | $1.29M | Buy |
13,620
+3,526
| +35% | +$335K | ﹤0.01% | 565 |
|
|
2023
Q4 | $901K | Buy |
10,094
+832
| +9% | +$74.3K | ﹤0.01% | 610 |
|
|
2023
Q3 | $676K | Buy |
9,262
+1,733
| +23% | +$127K | ﹤0.01% | 631 |
|
|
2023
Q2 | $626K | Sell |
7,529
-951
| -11% | -$79.1K | ﹤0.01% | 643 |
|
|
2023
Q1 | $646K | Buy |
8,480
+354
| +4% | +$27K | ﹤0.01% | 613 |
|
|
2022
Q4 | $674K | Sell |
8,126
-40
| -0.5% | -$3.32K | ﹤0.01% | 577 |
|
|
2022
Q3 | $648K | Buy |
8,166
+734
| +10% | +$58.2K | ﹤0.01% | 550 |
|
|
2022
Q2 | $552K | Buy |
7,432
+2,382
| +47% | +$177K | ﹤0.01% | 574 |
|
|
2022
Q1 | $454K | Buy |
5,050
+2,409
| +91% | +$217K | ﹤0.01% | 645 |
|
|
2021
Q4 | $295K | Buy |
+2,641
| New | +$295K | ﹤0.01% | 685 |
|